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Communicated by Riccardo Fodde 
 
ABSTRACT: Transforming growth factor-β (TGF-β) signalling plays a key role in colorectal cancer 
(CRC). Bone morphogenetic protein-4 (BMP4) is a member of the TGF-β family of signal 
transduction molecules. To examine if germline mutation in BMP4 causes CRC we analysed 504 
genetically enriched CRC cases (by virtue of early-onset disease, family history of CRC) for 
mutations in the coding sequence of BMP4. We identified three pathogenic mutations, p.R286X 
(g.8330C>T), p.W325C (g.8449G>T) and p.C373S (g.8592G>C), amongst the CRC cases which 
were not observed in 524 healthy controls. p.R286X localizes to the N-terminal of the TGF-β1 
prodomain truncating the protein prior to the active domain. p.W325C and p.C373S mutations are 
predicted from protein homology modelling with BMP2 to impact deleteriously on BMP4 
function. Segregation of p.C373S with adenoma and hyperplastic polyp in first-degree relatives of 
the case suggests germline mutations may confer a juvenile polyposis-type phenotype. These 
findings suggest mutation of BMP4 is a cause of CRC and the value of protein-based modelling in 
the elucidation of rare disease-causing variants. ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
Transforming growth factor-β (TGF-β; MIM# 190180) signalling plays a key role in developmental biology, 
cell proliferation, differentiation and migration (Xu and Pasche, 2007); and is increasingly recognized to be 
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important in cancer biology (Tenesa and Dunlop, 2009). Furthermore, germline mutations in the genes encoding 
the TGF-β signalling proteins, SMAD4 (Howe, et al., 1998; MIM# 600993) and BMPR1A (Howe, et al., 2001; 
MIM# 601299) have been shown to cause juvenile polyposis, an autosomal dominant polyposis syndrome which 
confers a high risk of colorectal cancer (CRC).   
Genome-wide association (GWA) studies have recently shown that common genetic variation in the gene 
encoding the TGF-β signalling protein BMP4 influences CRC risk (Houlston, et al., 2008). The bone 
morphogenetic protein-4 (BMP4; MIM# 112262; NM_001202.3) gene maps to 14q22.2 and is composed of 4 
exons. Multiple BMP4 transcripts are generated (Shore, et al., 1998), but only exons 3 and 4 are translated (van 
den Wijngaard, et al., 1996), from which a homodimer of two 408 amino acid BMP4 polypeptides is formed. Six 
cysteine residues form the critical protein folding motif (referred to as the cysteine knot) while a seventh cysteine 
is responsible for homodimerisation of BMP4 (McDonald and Hendrickson, 1993). This homodimer consisting of 
TGF-β1 prodomains and active domains (McDonald and Hendrickson, 1993) is proteolytically cleaved at two sites 
to generate the active ligand (Aono, et al., 1995). Mature BMP4 initiates TGF-β signalling by binding to type I 
(BMPR1A) and type II (BMPR2; MIM# 600799) serine or threonine kinase receptors, triggering intracellular 
SMAD-signalling (Schmierer and Hill, 2007). 
It is increasingly being recognised that both common variants and coding mutations of the same gene can 
confer cancer susceptibility, exemplified by CDH1 (MIM# 192090) in colorectal cancer (Houlston, et al., 2008; 
Richards, et al., 1999; Salahshor, et al., 2001). To examine if rare germline mutations in the coding region of 
BMP4 cause CRC we analysed 504 genetically enriched CRC cases.  
METHODS 
Subjects 
 
Five hundred and four CRC cases (298 male) were ascertained through the National Study of Colorectal Cancer 
(NSCCG; Penegar, et al., 2007) and the Royal Marsden Hospital NHS Trust Family History and DNA Registry 
(RMHNHST). All cases had histologically proven colorectal adenocarcinoma (International classification of 
diseases, 9th Revision [ICD9] codes 153 or 154) and none had previously been documented to have a diagnosis of 
a cancer syndrome known to be associated with increased CRC risk. To enhance our power to detect germline 
mutations, case selection was prioritized for early-age of onset (n=182 diagnosed <55 years, family history of CRC 
n=250) and microsatellite stable (MSS) disease (n=210). Samples from 524 healthy individuals collected through 
RMHNHST (219 males; mean age at sampling 58.0 years, SD 14.0), who did not have a personal history of 
malignancy at time of ascertainment served as a source of controls. Both cases and controls were UK residents and 
had self-reported European ancestry. 
The study was conducted with informed consent and ethical approval (MREC 02/0/097 and RMHNHST-
CCR1552) in accordance with the declaration of Helsinki.  
 
Molecular analyses 
 
Genomic DNA was salt-extracted from EDTA-venous blood samples (Miller, et al., 1988).  Amplification of 
genomic DNA was performed with 12.5ng DNA and PCR was carried out by use of Qiagen Multiplex Kit 
(QIAGEN Ltd, Crawley, UK). Sequencing was performed with Big Dye version 3.1 using ABI 3730xl semi-
automated sequencers (Applied Biosystems, Foster City, USA) in accordance with the manufacturer’s protocol. 
Sequence data was analysed using Mutation Surveyor (Soft Genetics, USA) and sequence changes were annotated 
against GenBank contig NC_000014.8 sequence data according to the nomenclature advocated by Human Genetic 
Variation (HGV; den Dunnen and Antonarakis, 2000; http://www.hgvs.org/).   
To assess allelic imbalance at 14q22.2-BMP4 in the CRCs from cases carrying germline BMP4 mutations, 
DNA was extracted from microdissected formalin fixed paraffin embedded (FFPE) tumors using Qiagen DNA 
Mini kits (QIAGEN Ltd., Crawley, UK). Loss of heterozygosity was assessed by comparing peak heights of PCR-
amplified germline and tumor exon fragments encompassing mutations using ABI 3730xl semi-automated 
sequencers and Mutation Surveyor software. E1930  Lubbe et al. 
Microsatellite instability (MSI) in CRCs was determined using BAT25
 and BAT26 markers which are highly 
sensitive MSI markers (Boland, et al., 1998), as previously described (Penegar, et al., 2007). Samples showing
 
novel alleles at either or both markers were assigned as MSI
 (corresponding to MSI-high).  
To assess promoter CpG island methylation of BMP4  (chr14:53,489,935-53,492,708 and 53,488,428-
53,488,631) germline genomic DNA and tumor DNA from microdissected FFPE tumors were subjected to 
bisulfite conversion and were purified using the EpiTect Bisulfite kit (QIAGEN Ltd., Crawley, UK). PCR 
amplification of the putative BMP4 sequence was performed on eluted DNA and search for differential 
methylation conducted by Pyrosequencing technology (QIAGEN Ltd., Crawley, UK) using biotinylated 
oligonucleotide primers. 
Details of all oligonucleotide primers used are shown in Supp. Table S1. 
 
Bioinformatic analyses 
 
We applied two in silico algorithms, PolyPhen (Ramensky, et al., 2002; http://genetics.bwh.harvard.edu/pph/) 
and SIFT (Ng and Henikoff, 2001; http://sift.jcvi.org/), to predict the putative effect of non-synonymous coding 
changes in BMP4 on expressed protein function. Protein sequence of BMP4 (NP_001193.2) was obtained from the 
NCBI Human RefSeq database (Pruitt, et al., 2005; http://www.ncbi.nlm.nih.gov/refseq/). PolyPhen scores were 
designated probably damaging (≥2.00), possibly damaging (1.50-1.99), potentially damaging (1.25-1.49), 
borderline (1.00-1.24), or benign (0.00-0.99) according to the classification proposed by Xi et al. 2004. SIFT 
scores were classified as intolerant (0.00-0.05), potentially intolerant (0.051-0.10), borderline (0.101-0.20), or 
tolerant (0.201-1.00) according to the classification proposed by Ng and Henikoff, 2001 and Xi et al., 2004.  
The effect of BMP4 mutations on the stability of BMP4, as well as the ability of BMP4 to interact with other 
proteins, was investigated by homology modelling using Molecular operating environment v2008.10 (MOE, 
Chemical Computing Group Inc. Montreal, Canada). The functionally inactive prodomain could not be modelled 
due to lack of crystallized structures of BMP4 and/or closely homologous proteins thus the structural analysis was 
limited to the active domain. BMP2 (NP_001191.1) shows the greatest similarity to BMP4 with a sequence 
identity of 90% and a similarity of 95% for the active domain. The active domains of BMP2 and BMP4 are also of 
similar length. Given the high sequence identity, similarity and length between the proteins, the effect of BMP4 
mutation in the active domain can be derived directly from the known crystal structure of BMP2. This also allowed 
for the generation of a homology model of BMP4 based upon the BMP2 structure.    
Two crystal structures of BMP2, 2goo (Pinto, et al., 2006) and 2h64 (Weber, et al., 2007) were obtained from 
The Protein Databank (Berman, et al., 2000; http://www.pdb.org/pdb/home/home.do) which served as templates 
for generation of the homology models of BMP4. Homology models were generated using the default settings with 
the Amber99 forcefield and medium model refinement. An overlay of the BMP4 homology model and the BMP2 
crystal structure showed that the backbones of both proteins align and that sidechains occupy the same orientation. 
 
RESULTS 
 
Complete sequence data of the coding regions of BMP4 and accompanying splice sites was obtained for all 504 
CRC cases and 524 controls. One common non-synonymous single nucleotide polymorphism (nsSNP) 
rs17563T>C (p.V152A) was found in both cases and controls at similar frequency (minor allele frequencies 0.44 
and 0.41 respectively).  
Five missense mutations, p.E93G (g.6788A>G), p.R226W (g.8150C>T), p.R287H (g.8334G>A), p.W325C 
(g.8449G>T) and p.C373S (g.8592G>C), and one truncating mutation, p.R286X (g.8330C>T), were identified in 
single individuals among the 504 CRC cases screened (Table 1). Four missense mutations, p.S154F (n=2; 
g.7935C>T), p.T225A (n=2; g.8147A>G), p.R226W and p.I381V (g.8615A>G), were identified in the 524 
controls (Table 1). Comparative amino acid sequence analysis revealed complete conservation of the amino acid 
sequence of BMP4 in eight species (human, chimpanzee, cow, rat, dog, chicken, frog, and zebrafish) at each of 
these positions (Figure 1). p.E96G is located in the functionally inactive prodomain of BMP4 and is predicted by Mutation in BMP4 and Colorectal Cancer Risk    E1931 
 
SIFT and PolyPhen to be benign/tolerated.  p.S154F and p.R226W are both predicted to be probably damaging or 
to affect the protein structure, with p.T225A predicted to be benign/tolerated. However, all three mutations map to 
the prodomain of BMP4 and are thus unlikely to have functional consequences a priori.  
p.R287H was identified in a female case diagnosed with rectal CRC at age 42 (ICD9 code 154.1). The 
individual had concomitant colorectal adenomas at diagnosis. p.R287H is located in the prodomain adjacent to the 
proteolytic S1 cleavage site (-R-A-K-R-; amino acids 289-292). Cleavage of the S1 site is necessary for 
subsequent cleavage at the S2 site (-R-I-S-R-; amino acids 253-256) (Cui, et al., 2001). A basic residue at position 
at amino acid 287 is prerequisite for site recognition/cleavage by furin (Watanabe, et al., 1993). Arginine and 
histidine are both basic amino acids and p.R287H is therefore unlikely to have any effect on the post-translational 
cleavage by furin. This mutation is predicted to be benign/tolerated by PolyPhen and SIFT (Table 1).  
Table 1. Predicted effects of non-synonymous coding changes in BMP4 on expressed protein function 
 
 
Mutation  Location in protein  Case/Control  PolyPhen score  SIFT score 
 
           
g.6788A>G;  p.E93G  Prodomain  Case  0.71 Benign  0.09 Potentially  intolerant 
g.7935C>T; p.S154F  Prodomain  Control  1.60  Possibly damaging  0.00  Intolerant 
g.8147A>G;  p.T225A Prodomain  Control  0.74 Benign  0.56 Tolerant 
g.8150C>T; p.R226W  Prodomain  Case/Control  2.09  Probably damaging  0.01  Intolerant 
g.8330C>T;  p.R286X  Prodomain  Case  N/A   N/A  
g.8334G>A;  p.R287H Prodomain  Case  0.43 Benign  0.37 Tolerant 
g.8449G>T; p.W325C  Active domain  Case  4.37  Probably damaging  0.00  Intolerant 
g.8592G>C; p.C373S  Active domain  Case  3.87  Probably damaging  0.00  Intolerant 
g.8615A>G; p.I381V  Active domain  Control  1.20  Benign  0.06  Potentially intolerant 
                    
 
g, position of mutation within genomic DNA (GenBank reference sequence NC_000014.8); N/A, Not applicable; p, position 
of mutation within protein (GenBank reference sequence NP_001193.2); PolyPhen, polymorphism phenotyping; SIFT, sorts 
intolerant from tolerant. 
 
The nonsense mutation, p.R286X, was identified in a female CRC case diagnosed with sigmoid MSS CRC 
(ICD9 code 153.3) at age 42 who at the time of diagnosis had no first-degree relative affected with CRC. p.R286X 
localizes to the N-terminal region of the TGF-β1 prodomain truncating the protein prior to the active domain 
(amino acids 292–408). Thus, BMP4 haploinsufficiency is likely to occur through nonsense-mediated RNA decay. 
The missense mutations p.C373S and p.W325C map to the active domain of BMP4. p.C373S was identified in 
a female case diagnosed with sigmoid CRC (ICD9 code 153.3) at age 34. The case’s father and brother who were 
diagnosed with colorectal adenomas at ages 67 and 36, respectively, have also been shown to carry the p.C373S 
mutation. In addition, one of the case’s sisters, also a carrier of p.C373S, had hyperplastic polyps diagnosed at age 
of 35. The cysteine 373 residue is essential for the correct formation of the cysteine knot (McDonald and 
Hendrickson, 1993). p.W325C was identified in a male familial CRC case diagnosed with rectal disease at age 62 
(ICD9 code 154.1). The patient’s brother had previously died of colon cancer (ICD9 code 1539.0) at the age 60. 
Both p.C373S and p.W325C are likely to be detrimental to the structure of BMP4 on the basis of PolyPhen and 
SIFT predictions (Table 1).  
Only one missense mutation, p.I381V localising to the genomic region encoding the functional TGF-β domain 
was identified in a healthy control. This amino acid substitution is predicted to be benign/potentially intolerant by 
PolyPhen and SIFT (Table 1).  
To further examine the impact of p.W325C, p.C373S and p.I381V mutations we modelled the effects of these 
amino acid substitutions on the structure of the BMP4 protein. Isoleucine 381 interacts with other residues due to 
its location within a lipophilic pocket, but the p.I381V mutation changes its lipophilic properties to a limited extent 
thereby maintaining its interactions with the other residues. This mutation is not, therefore, predicted to impact E1932  Lubbe et al. 
protein stability (Figure 2A). Two crystal structures (2goo and 2h64) show tryptophan 325 in two conformations. 
Both conformations show an edge-to-face interaction with tryptophan 322 but the tryptophan residue flips in 
orientation between the two conformations (Figure 2B). The p.W325C mutation reduces this edge-to-face 
interaction and is predicted to lower the stability of the protein. The p.C373S mutation (Figure 2C) is predicted to 
result in a less stable protein structure due as to the removal of a critical disulphide bond and cysteine knot motif. 
 
 
 
 
Figure 1. Amino acid sequence alignment of vertebrate BMP4.The upper figure shows a schematic representation of the human 
BMP4 gene (NM_001202.3) with the positions of exons and their translated protein domains. Both exon 3 and exon 4 are in the 
translated region (grey arrow). Filled green is the TGF beta prodomain and violet is the TGF beta active domain. Positions of 
mutations identified are indicated for cases (dark blue arrows) and controls (green arrows). The position of R226W seen in both 
cases and controls is indicated by a light blue arrow. The S1 and S2 furin cleavage sites are also shown. Comparative amino 
acid alignment follows the order of Pan troglodytes (Chimpanzee [XP_509954]), Macaca mulatta (Rhesus monkey 
[XP_001084801]), Canis familiaris (Dog [XP_851628]), Homo sapiens (Human [NP_001193]), Equus caballus (Horse 
[NP_001157442]), Bos taurus (Cow [NP_001039342]), Mus musculus (Mouse   [NP_031580.1]), Rattus norvegicus (Rat 
[NP_036959]), Gallus gallus (Chicken [NP_990568]), Xenopus tropicalis (Western clawed Frog [NP_001017034]), and 
Xenopus laevis (African clawed frog [NP_001081501]). 
 
Since BMP4 is known to associate with BMPR1A, protein-protein interactions were investigated between the 
BMP4-BMPR1A protein-complex. Tryptophan 325 of BMP4 is the only residue predicted to interact with 
BMPR1A as it is identical in the aligned sequence of BMP2 and BMP4.  Therefore, the crystal structure of BMP2 
was used as a model to analyse the effect of mutation on the protein-protein complex. Tryptophan 325 forms a π-
stacking interaction with arginine 88 and forms an edge-to-face interaction with phenylalanine 85 (Figure 2D). The 
mutation p.W325C is thus predicted to significantly reduce these interactions and result in reduced binding of 
BMPR1A to BMP4. Because multiple residues are involved in binding between both proteins it is difficult to 
predict if this variant would result in a complete loss of the formation of the BMP4-BMPR1A complex. 
Archival tumor blocks were available on CRCs from p.R286X and p.C373S. Using these we examined tumors 
for loss of heterozygosity indicative of BMP4 having a tumor suppressor role. In both cases no evidence of 
differential allelotype was seen between germline and tumor DNA (data not shown).  Using paired normal and 
tumor DNA samples we also failed to demonstrate differential methylation of the BMP4 promotor  (data not 
shown).  Mutation in BMP4 and Colorectal Cancer Risk    E1933 
 
 
 
 
 
Figure 2. Homology modelling of BMP4 using the structure of BMP2. A: Isoleucine 381 (green) within a lipophilic pocket 
(purple); B: The interactions formed by tryptophan 325 in two different conformations (purple and yellow) with tryptophan 322 
and tyrosine 385 (grey); C: The disulphide bridge formed by cysteine 373 (white); D: The interacting residues with tryptophan 
325 (white), BMP4 (grey) and BMPR1A (orange). 
DISCUSSION 
 
The BMP pathway is inactivated in a large proportion of sporadic CRC (Kodach, et al., 2008). Evidence for 
germline mutation in BMP4 having a role in CRC predisposition is provided by the study of inhibition of BMP4 
signalling by transgenic expression of noggin in the mouse intestine. This leads to the formation of numerous 
ectopic crypt units, perpendicular to the crypt-villus axis, changes which typify the juvenile polyposis syndrome 
(Haramis, et al., 2004).  
In this study we have sought to establish a direct relationship between germline mutation in BMP4 and risk of 
CRC. It can be difficult to prove that a particular rare variant observed is etiologic unless those variants are strong 
candidates. BMP signalling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin E1934  Lubbe et al. 
signalling and disruption of this signalling pathway has strong candidacy for CRC predisposition (He, et al., 2004). 
Direct evidence for this assertion is provided by the fact that inactivating mutations in SMAD4 (Howe, et al., 1998) 
and BMPR1A (Howe, et al., 2001), which, like BMP4, are members of the TGF-β superfamily cause the rare 
juvenile polyposis syndrome, which carries a very high risk of CRC. These data provide strong evidence that 
haploinsufficiency of BMP4 will increase CRC risk. Kryukov et al. have provided empiric evidence that about 
70% of missense mutations present at population frequencies of 1% or less probably contribute to the phenotype in 
which they are first identified (Kryukov, et al., 2007). While we identified six mutations in both case and controls, 
three and five of the mutations in the cases and controls respectively map to the pro-domain of the expressed 
protein and are very unlikely to have any functional consequences. On the basis of detailed bioinformatics and 
protein homology modelling, only the three case mutations are likely to have functional consequences on the 
expressed protein. Sequence variations in the coding region of BMP4, aside from rs17563, are rare in both 
European (Felder, et al., 2002; Weber, et al., 2008) and Chinese populations (Suzuki, et al., 2009). On the basis of 
collective data on over 1,300 healthy population controls screened in our study and previously reported data 
(Bakrania, et al., 2008; Felder, et al., 2002; Suzuki, et al., 2009; Weber, et al., 2008) we identified three BMP4 
mutations in our CRC cohort which are predicted to functionally deleterious on expressed BMP4 (none were 
identified in controls) would mean that there is more than a 90% probability that at least one of these variants 
contributes directly to the development of CRC.  
Although in part speculative the demonstration that colorectal adenomas segregated with the p.C373S mutation 
in the one family and the fact that the case harboring p.W325C had a first-degree relative affected with CRC 
suggests that BMP4 mutations are likely to confer a moderate-high risk of CRC.  
In our study we did not observe loss of the wild-type allele in CRC from mutation carriers, providing little 
support for a classical tumor suppressor model of carcinogenesis. Although we were unable to demonstrate 
differential methylation of the putative promoter region of BMP4  we cannot fully exclude the possibility of 
inactivation of the wild-type allele through hypermethylation as a basis of tumor development. Accepting this 
caveat there exists the possibility that BMP4 mutations may impact on risk through a dominant negative effect as 
has previously been shown for SMAD4 mutations causing juvenile polyposis (Howe, et al., 1998). 
Bmp signalling is a determinant of dorsal closure in Drosophila Melanogaster (Fernandez, et al., 2007), and in 
concert with Shh, growth factors and Wnt7a coordinates growth and anteroposterior, proximodistal, and 
dorsoventral axes morphogenesis (Basler and Struhl, 1994; Kingsley, 1994; Tickle, 1995). While we did not 
document any associated extra-colonic clinical feature in the cases in which we identified BMP4 mutations, 
intriguingly a relationship between genetic susceptibility to clefting and cancer risk is supported in some 
epidemiological studies (Bille, et al., 2005; Zhu, et al., 2002). Germline mutations in BMP4 have been suggested 
to be causal of cleft lip/palate (Suzuki, et al., 2009), anomalies kidney development (Weber, et al., 2008) and 
neural tube defects (Felder, et al., 2002). Aside from one truncating mutation (Suzuki, et al., 2009) all of the 
mutations on which these assertions rest are based on sequence variation predicted to have no functional 
consequence. Contiguous gene defects involving BMP4 have been implicated in etiology of eye, brain, and digit 
anomalies (Bakrania, et al., 2008) although carrier first-degree relatives of some of the affected individuals were 
shown to be phenotypically unaffected.  
There is increasing recognition that much of the excess familial risk of CRC is a consequence of rare disease-
causing variants. The use of next generation sequencing technologies to screen CRC cases for causal variants will 
require enunciation of variants through bioinformatic methodologies. This study serves to illustrate the use of 
protein homology modelling methods for such analyses.  
We have previously shown that SNPs close to the BMP antagonist, Gremlin-1 (GREM1; MIM# 603054) are 
associated with CRC risk (Jaeger, et al., 2008). Our findings provide a strong rationale for evaluating additional 
members of the TGF-β superfamily of genes for coding mutations. Furthermore our finding provides a strong 
rationale for screening other genes identified by GWA studies is likely to identify additional germline mutations, 
which may cause CRC.   
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SUPPLEMENTARY TABLES 
 
Supp. Table S1. Oligonucleotide primer pairs 
 
      
Mutation identification  Exon 3  A-F  GGCGCTCAGGATACTCAAGA 
   A-R  CTTACTTTCAGGCCGTGCAT 
   B-F  AAACCCGACAAACACACAGC 
   B-R  CCTAGCAAGAGTGCCGTCAT 
  Exon 4  A-F  TCTCAGGGATGCTGCTGAGG 
   A-R  AAGAGGGAGAGGGTGGTTGT 
   B-F  ATGGCCAAAGGTGACCAG 
   B-R  CCCAACCCTGAGCTATCTCTT 
   C-F  CCTCAAGGACTGCCTGATCTC 
   C-R  GGCTAGCCATTGAGGTGACT 
   D-F  CAGGTACCACCTTTTGACTTCC 
   D-R  CTGGTCAATTCTGTCAATTCCA 
      
Loss of heterozygosity assessment  p.R286X F  TCGTTACCTCAAGGGAGTGG 
   R  CGCTGTGAGTGATGCTTAGG 
  p.C373S F  TGACCACCTCAACTCAACCA 
   R  CATCCAGGTACAGCATGGAG 
      
CpG methylation assessment  Pyrosequencing 1-F GGATGCCACACTCACCTAGCTT 
   1-R  TTTCTGGGGATGGGAGCC* 
   1-S  GCCACACTCACCTAGC 
   2-F  *AACCTGCTCCAGCTAGGTGTTCT 
   2-R  CTACCAAGGGCTTCTCTTGTTTC 
   2-S  TCAGCCCAAGACCCC 
   3-F  TAGGGGCATTGGCAGGTA 
   3-R  GCAGAAGCCCTTTAAAAAGCC* 
   3-S  ACCAACACCTCAGGTC 
   4-F  AGAAAGGAAATCCCACCATGT 
   4-R  AGCAAATACTCCTTCAAGAATTT* E1938  Lubbe et al. 
   4-S  GGAAATCCCACCATGT 
   5-F  TAATGAGACTCCACCGCAGACA 
   5-R  TGAAGCCAGAGGATTTGGGG* 
   5-S  GCTCCCAGGGCTACT 
   6-F  *AGGAGCTCATGGCTCTGC 
   6-R  CATCAGCATTCGGTTACCAG 
   6-S  CAGGTATCAAACTAGCATGG 
      
      
  Sequencing 1-F  CATCGGGGAGACAAGCTAGA 
   1-R  CTGGAGGGGAGGATGTGG 
   2-F  AGCAGGACTGCGCTCTCTAC 
   2-R  GGCAGGAGAGCAGAAACAAG 
   3-F  AAAGTAAAGGATCGAACAGCTCA 
   3-R  GCCTCCGTCTGCTTTCTCTA 
   4-F  AATGTGGCCGAGGTTTTACA 
   4-R  GGACATCCCAGTAACTGCTTG 
   5-F  CTTCCAGCCCCTCGGAGT 
   5-R  GAGACGCAGTCCCTTCAGTG 
   6-F  ATGACGGCACTCTTGCTAGG 
   6-R  CCTGGTAACCGAATGCTGAT 
      
 
* Biotin label; F, forward primer; p, position of mutation within protein (GenBank reference sequence NP_001193.2); R, 
reverse primer; S, sequencing primer. 
All oligonucleotide primer pairs for BMP4 were designed using GenBank reference sequence NC_000014.8. 
 